High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis

Journal of Rheumatology

Volumn 28, Issue 4, 2001, Pages 719-727

  Verburg, R J ^a   Sont, J K ^a   Vliet Vlieland, T P M ^a   Landewe R B ^a   Boers, M ^a   Kievit, J ^a   Van Laar, J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Decision analysis; Hematopoietic stem cell transplantation; Markov model; Rheumatoid arthritis; Treatment strategies

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; AUTOTRANSPLANTATION; CHEMOTHERAPY; DISEASE COURSE; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGEVITY; MARKOV CHAINS; MIDDLE AGED; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

EID: 0035081527     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Quality of life in rheumatoid arthritis
2. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
3. Innovative treatment approaches for rheumatoid arthritis. Combination therapy
4. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: Preliminary findings in the generic health OMERACT study
5. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
6. Autologous bone-marrow transplantation for rheumatoid arthritis
7. Remission and immune reconstitution after T-cell-depleted stem-cell transplantation for rheumatoid arthritis
8. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
9. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease
10. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis
11. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis
12. Mortality in rheumatoid arthritis
13. Markov models in medical decision making: A practical guide
14. Primer on medical decision analysis. 5. Working with Markov processes
15. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
16. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)
17. Combination therapy of severe rheumatoid arthritis at an early stage of the disease
18. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
19. A trial of etanercept a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate
20. Treatment of rheumatoid arthritis with methotrexate alone sulfasalazine and hydroxychloroquine or a combination of all three medications
21. Combination therapy in rheumatoid arthritis: Updated systematic review
22. Randomised comparison of combined step-down prednisolone methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
23. Autologous haematopoietic stem cell transplants for autoimmune disease - Feasibility and transplant-related mortality
24. Autologous T cell depleted CD34+ peripheral blood stem cell transplantation in four patients with refractory rheumatoid arthritis and juvenile chronic arthritis
25. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide thiotepa and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care
26. Autologous blood stem cell transplantation for haematological malignancy: Treatment-related mortality of 2%
27. Haemopoietic stem cell transplantation in Australia 1992-95: A report from the Australian Bone Marrow Transplant Recipient Registry
28. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
29. Autologous and allogeneic transplantation for multiple myeloma at a single centre
30. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM
31. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver
32. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
33. Medical assessment by a Delphi group opinion technique
34. A utility maximization model for evaluation of health care programs
35. Social preferences for health states: An empirical evaluation of three measurement techniques
36. Utility measurement in patients with rheumatoid arthritis: Usefulness of the time trade-off method
37. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined stepdown prednisolone methotrexate and sulphasalazine with sulphasalazine alone
38. Standard gamble,time trade-off and rating scale: Experimental results on the ranking properties of QALYs
39. Valuing health states: A comparison of methods
40. Utility assessment in cancer patients: Adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores
41. Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone
42. Stem cell transplantation for severe autoimmune diseases: Progress and problems
43. Bone marrow transplant for rheumatoid arthritis: The costs of a cure
44. Risk taking in patients with rheumatoid arthritis: Are the risks of haemopoietic stem cell transplantation acceptable?
45. Willingness to accept risk in the treatment of rheumatic disease
46. Risk taking in patients with rheumatoid arthritis: Are the risks of haematopoietic stem cell transplantation acceptable?
47. Modeling the lifetime costs of rheumatoid arthritis